Waiv, a Paris-based medical testing startup spun out of biotech unicorn Owkin, has secured $33 million in a funding round co-led by OTB Ventures and Alpha Intelligence Capital. The new company aims to revolutionize cancer care by using artificial intelligence to enable more precise diagnostics and patient stratification. This significant investment will fuel its mission to make AI-powered precision testing the global standard in oncology.
A Strategic Spin-Out from Owkin
Waiv originated as the internal diagnostics division, Owkin Dx, within the French AI biotech firm Owkin. Over several years, the team grew from a small project into a 47-person unit with dedicated engineering, data science, and commercial teams. This substantial growth and specialized focus necessitated its evolution into an autonomous company to pursue its distinct development cycles.
The transition was structured as a spin-out, allowing Waiv to operate independently while Owkin remains a minority shareholder. CEO Meriem Sefta described the process as an incubation, where the activity matured within Owkin before needing to leave the nest. This separation enables Waiv to tailor its business strategy and timelines specifically to the diagnostics market.
Revolutionizing Diagnostics with AI
At its core, Waiv's technology leverages AI to analyze digital pathology images, providing a deeper characterization of tumors. This advanced analysis helps identify complex biomarkers that can reliably match patients to the therapies most likely to benefit them. The company's goal is to overcome the complexities that currently hinder the widespread application of precision medicine.
The company’s Destra platform delivers rapid results for a suite of tests, including its MSIntuit Suite and BRCAura for pre-screening. By extracting critical biological insights directly from standard H&E slides, Waiv reduces reliance on more complex methods like genomic sequencing. This integrated approach distinguishes it from competitors who focus narrowly on either genomics or pathology.
Fueling Growth and Global Expansion
The newly raised $33 million will be strategically allocated to accelerate Waiv's key priorities. A primary objective is to expand its portfolio of clinical tests and generate robust medical evidence to support their widespread adoption. The funding will help scale the deployment of its existing solutions in laboratories across the globe.
Another critical focus is deepening partnerships with the pharmaceutical industry, building on existing collaborations with firms like Merck and AstraZeneca. This capital will enable Waiv to co-develop new products and enhance clinical trials through advanced biomarker discovery. These collaborations are central to the company's strategy for innovation and market penetration.
From its inception, Waiv has pursued an international strategy, with CEO Meriem Sefta emphasizing a focus beyond France. The company is targeting the United States and Europe as its key markets for expansion. This global outlook is crucial for achieving its mission of establishing a new worldwide standard for oncology diagnostics.
Investor Confidence and Market Impact
The funding round signals strong investor confidence in Waiv's potential to transform the oncology landscape. Karol Szubstarski, a partner at lead investor OTB Ventures, stated that Waiv brings a level of technological advancement that the field has been waiting for. This endorsement highlights the market's belief in the company's world-class team and innovative platform.
With this substantial financial backing, Waiv is well-positioned to accelerate its mission of integrating AI-powered diagnostics into standard oncology care. The investment will enhance its technological capabilities, strengthen its industry partnerships, and expand its global footprint. Ultimately, Waiv's progress promises to deliver more precise treatments and improved outcomes for cancer patients worldwide.